Format

Send to

Choose Destination
Vaccine. 2011 Jan 17;29(4):712-20. doi: 10.1016/j.vaccine.2010.11.022. Epub 2010 Nov 27.

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

Author information

1
Novartis Vaccines Institute for Global Health, Via Fiorentina 1, 53100 Siena, Italy. francesca.micoli@novartis.com

Abstract

An efficacious, low cost vaccine against typhoid fever, especially for young children, would make a major impact on disease burden in developing countries. The virulence capsular polysaccharide of Salmonella Typhi (Vi) coupled to recombinant mutant Pseudomonas aeruginosa exoprotein A (Vi-rEPA) has been shown to be highly efficacious. We investigated the use of carrier proteins included in infant vaccines, standardized the conjugation process and developed key assays required for routine lot release at production scale. Vi from a BSL1 organism, Citrobacter freundii, strain WR7011, was used as an alternative to Vi from S. Typhi. We showed that Vi conjugated to CRM(197), a non-toxic mutant of diphtheria toxin, widely used in commercial vaccines, was produced at high yield. Vi-CRM(197) proved immunogenic in animal studies, even without adjuvant. Thus, Vi-CRM(197) appears to be a suitable candidate for the development of a commercially viable, effective typhoid vaccine for developing countries.

PMID:
21115057
PMCID:
PMC4163788
DOI:
10.1016/j.vaccine.2010.11.022
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center